Scrip
US FDA grants priority review to InterMune's pirfenidone
06 January 2010
Katie McQue
Please Login to read the full article.
06 January 2010
Katie McQue
katie.mcque@informa.com
The US FDA has granted priority review status to the NDA for InterMune's idiopathic pulmonary fibrosis (IPF) candidate pirfenidone.
This move gives the potential to accelerate the drug's approval by reducing the targeted review period from 10 months to six months. The agency has set the...
Please Login to read the full article.
RELATED CONTENT
NEWS
- InterMune files pirfenidone for pulmonary fibrosis in US on mixed data
- GNI files pirfenidone for pulmonary fibrosis in China
- US FDA panel to review InterMune's pirfenidone for idiopathic pulmonary fibrosis
- FDA panel backs InterMune's pulmonary fibrosis drug Esbriet despite reservations
COMMENT
Other Informa Comment
FEATURES
- Amarin focused on CV disease to pump new life into company
- Face-to-Face: Allon targets tau pathology with lead drug davunetide
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
